Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning

PURPOSE: Inhibitors of the mammalian target of rapamycin (mTOR) kinase have shown clinical activity in several lymphoma subtypes. Sirolimus, an mTOR inhibitor, also has activity in the treatment and prophylaxis of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Armand, Philippe, Gannamaneni, Supriya, Kim, Haesook T., Cutler, Corey S., Ho, Vincent T., Koreth, John, Alyea, Edwin P., LaCasce, Ann S., Jacobsen, Eric D., Fisher, David C., Brown, Jennifer R., Canellos, George P., Freedman, Arnold S., Soiffer, Robert J., Antin, Joseph H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2008
Assuntos:
Lymphoma and Myeloma
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2645102/
https://ncbi.nlm.nih.gov/pubmed/19001324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.17.7279
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados